ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinoma
Feyerabend S, Boegemann M, Goebell P, Stoeckle M, Nepert D, Wride K, Thomas D, Loehr A, Simmons A, Grivas P, Chowdhury S (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 41
Pages Range: 324-324
DOI: 10.1093/annonc/mdy283.137
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Münster
Germany (DE)
University of Washington
United States (USA) (US)
Clovis Oncology
United States (USA) (US)
Guy's and St Thomas' (NHS Foundation Trust)
United Kingdom (GB)
Universitätsklinikum des Saarlandes (UKS)
Germany (DE)
Germany (DE)
University of Washington
United States (USA) (US)
Clovis Oncology
United States (USA) (US)
Guy's and St Thomas' (NHS Foundation Trust)
United Kingdom (GB)
Universitätsklinikum des Saarlandes (UKS)
Germany (DE)
How to cite
APA:
Feyerabend, S., Boegemann, M., Goebell, P., Stoeckle, M., Nepert, D., Wride, K.,... Chowdhury, S. (2018). ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinoma. (pp. 324-324).
MLA:
Feyerabend, S., et al. "ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinoma." 2018. 324-324.
BibTeX: Download